Cargando…
Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension
Hypertension can begin in childhood; elevated blood pressure in children is known as pediatric hypertension. Contrary to adult hypertension, there is a scarcity of commercial medications suitable for the treatment of pediatric hypertension. The aim of this study was to develop orally dispersible fil...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535373/ https://www.ncbi.nlm.nih.gov/pubmed/37765131 http://dx.doi.org/10.3390/ph16091323 |
_version_ | 1785112614278266880 |
---|---|
author | Abdelkader, Hamdy Abdel-Aleem, Jelan A. Mousa, Heba Salah Elgendy, Marwa O. Al Fatease, Adel Abou-Taleb, Heba A. |
author_facet | Abdelkader, Hamdy Abdel-Aleem, Jelan A. Mousa, Heba Salah Elgendy, Marwa O. Al Fatease, Adel Abou-Taleb, Heba A. |
author_sort | Abdelkader, Hamdy |
collection | PubMed |
description | Hypertension can begin in childhood; elevated blood pressure in children is known as pediatric hypertension. Contrary to adult hypertension, there is a scarcity of commercial medications suitable for the treatment of pediatric hypertension. The aim of this study was to develop orally dispersible films (ODFs) loaded with captopril for the treatment of hypertension in children. Captopril-loaded ODFs were composed of different blends of synthetic polymers, such as polyvinyl alcohol (PVA) and polyvinyl pyrrolidone, and natural polymers, such as sodium alginate (SA) and gelatin. The ODFs were characterized based on their mechanical and thermal properties, drug content, surface morphology, in vitro disintegration, in vitro release, and bioavailability. A novel HPLC method with precolumn derivatization was developed to precisely and selectively determine captopril levels in plasma. A low concentration of PVA and a high concentration of SA generated ODFs with faster hydration and disintegration rates. SA-based films exhibited fast disintegration properties (1–2 min). The optimized modified-release film (F2) showed significant (p < 0.05) enhancement in bioavailability (AUC = 1000 ng min/mL), with a value 1.43 times that of Capoten(®) tablets (701 ng min/mL). While the plasma concentration peaking was in favor of the immediate-release tablet, T(max) was significantly prolonged by 5.4 times for the optimized ODF (3.59 h) compared with that of the tablets (0.66 h). These findings indicate uniform and sustained plasma concentrations, as opposed to the pulsatile and rapid plasma peaking of captopril from the immediate-release tablets. These findings suggest that the modified release of oral films could offer more favorable plasma profiles and better control of hypertension than the conventional release tablets. |
format | Online Article Text |
id | pubmed-10535373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105353732023-09-29 Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension Abdelkader, Hamdy Abdel-Aleem, Jelan A. Mousa, Heba Salah Elgendy, Marwa O. Al Fatease, Adel Abou-Taleb, Heba A. Pharmaceuticals (Basel) Article Hypertension can begin in childhood; elevated blood pressure in children is known as pediatric hypertension. Contrary to adult hypertension, there is a scarcity of commercial medications suitable for the treatment of pediatric hypertension. The aim of this study was to develop orally dispersible films (ODFs) loaded with captopril for the treatment of hypertension in children. Captopril-loaded ODFs were composed of different blends of synthetic polymers, such as polyvinyl alcohol (PVA) and polyvinyl pyrrolidone, and natural polymers, such as sodium alginate (SA) and gelatin. The ODFs were characterized based on their mechanical and thermal properties, drug content, surface morphology, in vitro disintegration, in vitro release, and bioavailability. A novel HPLC method with precolumn derivatization was developed to precisely and selectively determine captopril levels in plasma. A low concentration of PVA and a high concentration of SA generated ODFs with faster hydration and disintegration rates. SA-based films exhibited fast disintegration properties (1–2 min). The optimized modified-release film (F2) showed significant (p < 0.05) enhancement in bioavailability (AUC = 1000 ng min/mL), with a value 1.43 times that of Capoten(®) tablets (701 ng min/mL). While the plasma concentration peaking was in favor of the immediate-release tablet, T(max) was significantly prolonged by 5.4 times for the optimized ODF (3.59 h) compared with that of the tablets (0.66 h). These findings indicate uniform and sustained plasma concentrations, as opposed to the pulsatile and rapid plasma peaking of captopril from the immediate-release tablets. These findings suggest that the modified release of oral films could offer more favorable plasma profiles and better control of hypertension than the conventional release tablets. MDPI 2023-09-19 /pmc/articles/PMC10535373/ /pubmed/37765131 http://dx.doi.org/10.3390/ph16091323 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Abdelkader, Hamdy Abdel-Aleem, Jelan A. Mousa, Heba Salah Elgendy, Marwa O. Al Fatease, Adel Abou-Taleb, Heba A. Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title | Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title_full | Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title_fullStr | Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title_full_unstemmed | Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title_short | Captopril Polyvinyl Alcohol/Sodium Alginate/Gelatin-Based Oral Dispersible Films (ODFs) with Modified Release and Advanced Oral Bioavailability for the Treatment of Pediatric Hypertension |
title_sort | captopril polyvinyl alcohol/sodium alginate/gelatin-based oral dispersible films (odfs) with modified release and advanced oral bioavailability for the treatment of pediatric hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535373/ https://www.ncbi.nlm.nih.gov/pubmed/37765131 http://dx.doi.org/10.3390/ph16091323 |
work_keys_str_mv | AT abdelkaderhamdy captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension AT abdelaleemjelana captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension AT mousahebasalah captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension AT elgendymarwao captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension AT alfateaseadel captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension AT aboutalebhebaa captoprilpolyvinylalcoholsodiumalginategelatinbasedoraldispersiblefilmsodfswithmodifiedreleaseandadvancedoralbioavailabilityforthetreatmentofpediatrichypertension |